消除麻疹进展——东地中海区域,2013—2019年
世界卫生组织东地中海区域21个国家于1997年通过消除麻疹决议,2015年将该目标纳入《2016—2020年东地中海疫苗行动计划》。本报告描述2013—2019年消除麻疹进展:MCV1覆盖率从2013年79%升至2018年82%,MCV2从59%升至74%;确诊麻疹发病率从2013年33.5/100万升至2018年91.2/100万,2019年降至23.3/100万。
要点
- MCV1覆盖率从2013年79%升至2018年82%,MCV2从59%升至74%。
- 确诊麻疹发病率从2013年33.5/100万升至2018年91.2/100万,2019年降至23.3/100万。
核心结论
- 为实现东地中海区域消除麻疹目标,亟需提高消除麻疹工作的可见度,并持续、可预测地投入以提高MCV1和MCV2覆盖率、开展高质量补充免疫活动并覆盖未获得免疫服务或生活在内乱地区的高风险人群。
研究设计与样本
- 本报告描述世界卫生组织东地中海区域21个国家2013—2019年消除麻疹进展,并更新此前报告。
主要发现
- 估计MCV1覆盖率从2013年79%升至2018年82%,MCV2覆盖率从2013年59%升至2018年74%。
- 报告确诊麻疹发病率从2013年33.5/100万升至2018年91.2/100万,巴基斯坦、索马里和也门发生大规模暴发,2019年发病率降至23.3/100万。
- 2019年 discarded nonmeasles cases 率为5.4/10万人口。
关键数值与推荐
- 1997年东地中海区域委员会第41届会议通过消除麻疹决议。
- 2015年消除麻疹目标纳入《2016—2020年东地中海疫苗行动计划》,并在区域委员会第62届会议获批。
- 四管齐下策略:通过常规免疫服务使每个国家每个地区MCV1覆盖率达≥95%;通过常规2剂接种程序或补充免疫活动使每个国家每个地区MCV2覆盖率达≥95%;所有国家开展高质量个案监测;提供最佳麻疹临床病例管理,包括补充维生素A。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 1997, during the 41st session of the Regional Committee for the Eastern Mediterranean, the 21 countries in the World Health Organization (WHO) Eastern Mediterranean Region* (EMR) passed a resolution to eliminate† measles (1). In 2015, this goal was included as a priority in the Eastern Mediterranean Vaccine Action Plan 2016-2020 (EMVAP) (2), endorsed at the 62nd session of the Regional Committee (3). To achieve this goal, the WHO Regional Office for the Eastern Mediterranean developed a four-pronged strategy: 1) achieve ≥95% vaccination coverage with the first dose of measles-containing vaccine (MCV1) among children in every district of each country through routine immunization services; 2) achieve ≥95% vaccination coverage with a second MCV dose (MCV2) in every district of each country either through implementation of a routine 2-dose vaccination schedule or through supplementary immunization activities§ (SIAs); 3) conduct high-quality, case-based surveillance in all countries; and 4) provide optimal measles clinical case management, including dietary supplementation with vitamin A (4). This report describes progress toward measles elimination in EMR during 2013-2019 and updates a previous report (5). Estimated MCV1 coverage increased from 79% in 2013 to 82% in 2018. MCV2 coverage increased from 59% in 2013 to 74% in 2018. In addition, during 2013-2019, approximately 326.4 million children received MCV during SIAs. Reported confirmed measles incidence increased from 33.5 per 1 million persons in 2013 to 91.2 in 2018, with large outbreaks occurring in Pakistan, Somalia, and Yemen; incidence decreased to 23.3 in 2019. In 2019, the rate of discarded nonmeasles cases¶ was 5.4 per 100,000 population. To achieve measles elimination in the EMR, increased visibility of efforts to achieve the measles elimination goal is critically needed, as are sustained and predictable investments to increase MCV1 and MCV2 coverage, conduct high-quality SIAs, and reach populations at risk for not accessing immunization services or living in areas with civil strife.
引用
- Goodson JL, Teleb N, Ashmony H, et al. Progress Toward Measles Elimination - Eastern Mediterranean Region, 2013-2019. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32298253. doi:10.15585/mmwr.mm6915a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。